InvestorsHub Logo
Followers 4
Posts 1198
Boards Moderated 0
Alias Born 10/03/2015

Re: investor_matt post# 246

Friday, 07/01/2016 11:27:02 PM

Friday, July 01, 2016 11:27:02 PM

Post# of 977
Trading volume is low because many are waiting for the ASH abstract before jumping in/out TRIL. There is not much expectation as tt-621 is valued less than $50 million. Since many tumors express CD47, any PR in P1 will make tti-621 + anti PD1 combo every pharma would die for. CELG described their
anti-cd47 mAb as "holy grail" , "disruptve" "we know its going to be highly effective"